Novel management of oral cancer: A paradigm of predictive oncology

Clinical Medicine and Research

Volumn 2, Issue 4, 2004, Pages 233-242

  Sudbø, Jon ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anti inflammatory agents; Carcinoma; Carcinoma in situ; Cyclooxygenase 2; Epidermal growth factor; Leukoplakia; Molecular therapeutics; Non steroidal; Oral; Receptor; Squamous cell

Indexed keywords

ARTICLE; RETRACTED ARTICLE; GENETIC SCREENING; GENETICS; HUMAN; LEUKOPLAKIA; MOUTH TUMOR; PRECANCER; PREDICTION AND FORECASTING; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA;

TUMOR MARKER;

CARCINOMA, SQUAMOUS CELL; GENETIC SCREENING; HUMANS; LEUKOPLAKIA, ORAL; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 27744557989     PISSN: 15394182     EISSN: 15546179     Source Type: Journal    
DOI: 10.3121/cmr.2.4.233     Document Type: Article

References (90)

1. Scully C, Porter S. ABC of oral health: swellings and red, white, and pigmented lesions. BMJ. 2000;321:225-228. [PMC free article] [PubMed]
2. Scully C, Porter S. ABC of oral health. Oral cancer. BMJ. 2000;321:97-100. [PMC free article] [PubMed]
3. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33. [PubMed]
4. Mork J. Forty years of monitoring head and neck cancer in Norway—no good news. Anticancer Res. 1998;18:3705-3708. [PubMed]
5. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345:1890-1900. [PubMed]
6. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys. 1989;17:691-694. [PubMed]
7. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184-194. [PubMed]
8. Cancer in Norway 2000. Institute of Population-based Cancer Research; 2003. The Cancer Registry of Norway.
9. Waldron CA, Shafer WG. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Cancer. 1975;36:1386-1392. [PubMed]
10. Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol. 1986;61:373-381. [PubMed]
11. Silverman S, Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984;53:563-568. [PubMed]
12. Silverman S, Jr, Gorsky M. Epidemiologic and demographic update in oral cancer: California and national data—1973 to 1985. J Am Dent Assoc. 1990;120:495-499. [PubMed]
13. Brunin F, Mosseri V, Jaulerry C, Point D, Cosset JM, Rodriguez J. Cancer of the base of the tongue: past and future. Head Neck. 1999;21:751-759. [PubMed]
14. Suarez P, Batsakis JG, el-Naggar AK. Leukoplakia: still a gallimaufry or is progress being made?— A review. Adv Anat Pathol. 1998;5:137-155. [PubMed]
15. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I. Histological typing of cancer and precancer of the oral mucosa. 2nd ed. London: Springer Verlag; 1997.
16. Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;79:321-329. [PubMed]
17. Jones AS. Prognosis in mouth cancer: tumour factors. Eur J Cancer B Oral Oncol. 1994;30B:8-15. [PubMed]
18. Schantz SP, Ostroff JS. Novel approaches to the prevention of head and neck cancer. Proc Soc Exp Biol Med. 1997;216:275-282. [PubMed]
19. Warnakulasuriya S. Lack of molecular markers to predict malignant potential of oral precancer. J Pathol. 2000;190:407-409. [PubMed]
20. Warnakulasuriya S. Histological grading of oral epithelial dysplasia: revisited. J Pathol. 2001;194:294-297. [PubMed]
21. Karabulut A, Reibel J, Therkildsen MH, Praetorius F, Nielsen HW, Dabelsteen E. Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med. 1995;24:198-200. [PubMed]
22. Sudbø J, Bryne M, Johannessen AC, Kildal W, Danielsen HE, Reith A. Comparison of histological grading and large scale genomic status (DNA ploidy) as prognostic tools in oral dysplasia. J Pathol. 2001;194:303-310. [PubMed]
23. Mao L, El-Naggar AK, Fan YH, Lee JS, Lippman SM, Kayser S, Lotan R, Hong WK. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res. 1996;56:5600-5604. [PubMed]
24. Mao L, Lee JS, Fan YH, Ro JY, Batsakis JG, Lippman S, Hittelman W, Hong WK. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med. 1996;2:682-685. [PubMed]
25. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, Berean K, Epstein JB, Priddy R, Le ND, Zhang L. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000;6:357-362. [PubMed]
26. Sudbø J, Kildal W, Risberg B, Koppang HS, Danielsen HE, Reith A. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med. 2001;344:1270-1278. [PubMed]
27. Sen S. Aneuploidy and cancer. Curr Opin Oncol. 2000;12:82-88. [PubMed]
28. Gardner RD, Burke DJ. The spindle checkpoint: two transitions, two pathways. Trends Cell Biol. 2000;10:154-158. [PubMed]
29. Ried T, Heselmeyer-Haddad K, Blegen H, Schrock E, Auer G. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer. 1999;25:195-204. [PubMed]
30. Cahill DP, da Costa LT, Carson-Walter EB, Kinzler KW, Vogelstein B, Lengauer C. Characterization of MAD2B and other mitotic spindle checkpoint genes. Genomics. 1999;58:181-187. [PubMed]
31. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643-649. [PubMed]
32. Tanke HJ, van Ingen EM. A reliable Feulgen-acriflavine-SO2 staining procedure for quantitative DNA measurements. J Histochem Cytochem. 1980;28:1007-1013. [PubMed]
33. Sudbø J, Ried T, Bryne M, Kildal W, Danielsen H, Reith A. Abnormal DNA content predicts the occurence of carcinomas in non-dysplastic oral white patches. Oral Oncol. 2001;37:558-565. [PubMed]
34. Sudbø J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbø A, Sagen S, Bryne M, El-Naggar A, Risberg B, Evensen JF, Reith A. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med. 2004;350:1405-1413. [PubMed]
35. Sudbø J, Kildal W, Johannessen AC, Koppang HS, Sudbø A, Danielsen HE, Risberg B, Reith A. Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol. 2002;20:456-462. [PubMed]
36. Bouquot JE, Ephros H. Erythroplakia: the dangerous red mucosa. Pract Periodontics Aesthet Dent. 1995;7:59-67. [PubMed]
37. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol. 1994;12:851-873. [PubMed]
38. Greenspan D, Jordan RC. The white lesion that kills—aneuploid dysplastic oral leukoplakia. N Engl J Med. 2004;350:1382-1384. [PubMed]
39. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst. 1998;90:1514-1528. [PubMed]
40. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res. 2002;8:314-346. [PubMed]
41. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63:1727-1730. [PubMed]
42. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996;56:2488-2492. [PubMed]
43. Jang SJ, Chiba I, Hirai A, Hong WK, Mao L. Multiple oral squamous epithelial lesions: are they genetically related? Oncogene. 2001;20:2235-2242. [PubMed]
44. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6:963-968. [PubMed]
45. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res. 2000;6:1702-1710. [PubMed]
46. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med. 2001;344:1323-1326. [PubMed]
47. Côté RA, editor. Systematized nomenclature of medicine. 2nd ed. Skokie, Illinois: College of American Pathologists; 1979.
48. Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer. 2002;2:537-543. [PubMed]
49. Boardman LA. Heritable colorectal cancer syndromes: recognition and preventive management. Gastroenterol Clin North Am. 2002;31:1107-1131. [PubMed]
50. Lippman SM, Hong WK. Cancer prevention by delay [Commentary re: J. A. O'Shaughnessy et al., Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8:314-346, 2002.] Clin Cancer Res. 2002;8:305-313. [PubMed]
51. Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res. 2002;62:5119-5125. [PubMed]
52. Sporn MB. The war on cancer: a review. Ann N Y Acad Sci. 1997;833:137-146. [PubMed]
53. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315:1501-1505. [PubMed]
54. Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, Martin JW, Hays GL, Goepfert H, Hong WK. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med. 1993;328:15-20. [PubMed]
55. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ, Hong WK. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med. 1995;332:1405-1410. [PubMed]
56. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323:795-801. [PubMed]
57. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst. 2000;92:977-986. [PubMed]
58. Lam S, Xu X, Parker-Klein H, Le Riche JC, MacAulay C, Guillaud M, Coldman A, Gazdar A, Lotan R. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia. Int J Oncol. 2003;23:1607-1613. [PubMed]
59. Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El- Naggar AK, Lewin JS, Lippman SM, Hong WK. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg. 1999;125:1083-1089. [PubMed]
60. Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, Clayman G, Lee JJ, Lee JS, Hittelman WN, Lippman SM, Hong WK. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst. 1998;90:1545-1551. [PubMed]
61. Sudbø J, Ristimäki A, Sondresen JE, Kildal W, Boysen M, Koppang HS, Reith A, Risberg B, Nesland JM, Bryne M. Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol. 2003;39:497-505. [PubMed]
62. Han S, Roman J. Suppression of prostaglandin E2 receptor subtype EP2 by PPAR gamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun. 2004;314:1093-1099. [PubMed]
63. Pomerantz RG, Grandis JR. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr Oncol Rep. 2003;5:140-146. [PubMed]
64. Ke LD, Adler-Storthz K, Clayman GL, Yung AW, Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck. 1998;20:320-327. [PubMed]
65. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579-3584. [PubMed]
66. Rubin Grandis J, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res. 1998;4:13-20. [PubMed]
67. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000;6:1024-1028. [PubMed]
68. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology. 2001;120:1713-1719. [PubMed]
69. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278:35451-35457. [PubMed]
70. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8:289-293. [PubMed]
71. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem. 2002;277:18649-18657. [PubMed]
72. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ. Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2. Cancer Res. 1997;57:1081-1085. [PubMed]
73. Zakar T, Mijovic JE, Eyster KM, Bhardwaj D, Olson DM. Regulation of prostaglandin H2 synthase-2 expression in primary human amnion cells by tyrosine kinase dependent mechanisms. Biochim Biophys Acta. 1998;1391:37-51. [PubMed]
74. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res. 2003;9:1566-1572. [PubMed]
75. Chen Z, Zhang X, Wang Z, Li M, Grandis JR, Shin DM. A possible interaction between epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) mediated pathways in squamous cell carcinoma of the head and neck (SCCHN) [abstract] Proc Am Assoc Cancer Res. 2003;44:439. Abstract 2242.
76. Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R, Pals ST. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 2004;90:224-229. [PMC free article] [PubMed]
77. Han C, Leng J, Demetris AJ, Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 2004;64:1369-1376. [PubMed]
78. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS. 3- phosphoinositidedependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2- independent target for celecoxib in prostate cancer cells. Cancer Res. 2004;64:1444-1451. [PubMed]
79. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol. 2004;67:1469-1478. [PubMed]
80. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 2004;23:63-75. [PubMed]
81. Bartsch H, Nair J. Exocyclic DNA adducts as secondary markers for oxidative stress: applications in human cancer etiology and risk assessment. Adv Exp Med Biol. 2001;500:675-686. [PubMed]
82. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferatoractivated receptors alpha and gamma are activated by indomethacin and other non-steroidal antiinflammatory drugs. J Biol Chem. 1997;272:3406-3410. [PubMed]
83. Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, Heasley LE, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol. 2002;62:1207-1214. [PubMed]
84. Pang L, Nie M, Corbett L, Knox AJ. Cyclooxygenase-2 expression by nonsteroidal antiinflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. J Immunol. 2003;170:1043-1051. [PubMed]
85. Clay CE, Atsumi GI, High KP, Chilton FH. Early de novo gene expression is required for 15- deoxy-Delta 12,14 prostaglandin J2-induced apoptosis in breast cancer cells. J Biol Chem. 2001;276:47131-47135. [PubMed]
86. Bartsch H. Studies on biomarkers in cancer etiology and prevention: a summary and challenge of 20 years of interdisciplinary research. Mutat Res. 2000;462:255-279. [PubMed]
87. Shaik MS, Chatterjee A, Singh M. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferatoractivated receptor-gamma. Clin Cancer Res. 2004;10:1521-1529. [PubMed]
88. Hashimoto K, Ethridge RT, Evers BM. Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. Int J Gastrointest Cancer. 2002;32:7-22. [PubMed]
89. Sudbø J. Kjemoprevensjon av munnhulekreft [Chemoprevention of oral cancer] [Article in Norwegian] Tidsskr Nor Laegeforen. 2003;123:1518-1521. [PubMed]
90. Jin Z, Gao F, Flagg T, Deng X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem. 2004;279:40209-40219. [PubMed]